Related Experiment Video

Updated: Jun 24, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Impact of sitagliptin on markers of beta-cell function: a meta-analysis

Daniel M Riche1, Honey E East, Krista D Riche

  • 1Department of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi 39216, USA. driche@sop.umsmed.edu

The American Journal of the Medical Sciences
|March 27, 2009
PubMed
Abstract

Insights

Dipeptidyl peptidase-IV inhibitors like sitagliptin improve beta-cell function in type 2 diabetes patients compared to placebo. However, they show no significant benefit over other treatments regarding beta-cell function or activity.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes is characterized by progressive beta-cell dysfunction and failure.
  • Dipeptidyl peptidase-IV (DPP-IV) inhibitors are investigated for their potential to improve beta-cell function and survival.
  • Key preclinical measures include the homeostasis model assessment of beta-cell (HOMA-beta) index and the proinsulin/insulin ratio (PI/IR).

Purpose of the Study:

  • To systematically evaluate the effects of sitagliptin on beta-cell function using meta-analysis.
  • To compare sitagliptin's efficacy against placebo and active controls for specific beta-cell function markers.

Main Methods:

  • A systematic literature search identified randomized controlled trials of sitagliptin therapy up to July 2008.
  • A random-effects model meta-analysis assessed HOMA-beta index and PI/IR changes versus placebo.
  • Subgroup analyses, including active controls, were performed on eligible studies.

Main Results:

  • Sitagliptin significantly improved HOMA-beta index by 12.03% and decreased PI/IR by -0.06 compared to placebo across 11 and 8 trials, respectively.
  • In subgroup analyses, sitagliptin was inferior to active controls for HOMA-beta index but showed no significant difference in PI/IR.

Conclusions:

  • While sitagliptin improves beta-cell function markers (HOMA-beta, PI/IR) compared to placebo, DPP-IV inhibitors do not appear to offer benefits over other agents.
  • The long-term impact of DPP-IV inhibitors on preventing beta-cell dysfunction requires further investigation.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.